173 related articles for article (PubMed ID: 24481662)
1. EMMPRIN co-expressed with matrix metalloproteinases predicts poor prognosis in patients with osteosarcoma.
Futamura N; Nishida Y; Urakawa H; Kozawa E; Ikuta K; Hamada S; Ishiguro N
Tumour Biol; 2014 Jun; 35(6):5159-65. PubMed ID: 24481662
[TBL] [Abstract][Full Text] [Related]
2. Increased expression of membrane-type matrix metalloproteinase-1 is correlated with poor prognosis in patients with osteosarcoma.
Uchibori M; Nishida Y; Nagasaka T; Yamada Y; Nakanishi K; Ishiguro N
Int J Oncol; 2006 Jan; 28(1):33-42. PubMed ID: 16327977
[TBL] [Abstract][Full Text] [Related]
3. EMMPRIN expression is associated with metastatic progression in osteosarcoma.
Kim HS; Kim HJ; Lee MR; Han I
BMC Cancer; 2021 Sep; 21(1):1059. PubMed ID: 34565336
[TBL] [Abstract][Full Text] [Related]
4. Gelatinase A, membrane type 1 matrix metalloproteinase, and extracellular matrix metalloproteinase inducer mRNA expression: correlation with invasive growth of breast cancer.
Dalberg K; Eriksson E; Enberg U; Kjellman M; Bäckdahl M
World J Surg; 2000 Mar; 24(3):334-40. PubMed ID: 10658069
[TBL] [Abstract][Full Text] [Related]
5. ADAM17 is associated with EMMPRIN and predicts poor prognosis in patients with uterine cervical carcinoma.
Xu Q; Ying M; Chen G; Lin A; Xie Y; Ohara N; Zhou D
Tumour Biol; 2014 Aug; 35(8):7575-86. PubMed ID: 24793016
[TBL] [Abstract][Full Text] [Related]
6. Calcifying Cystic Odontogenic Tumour: immunohistochemical expression of matrix metalloproteinases, their inhibitors (TIMPs and RECK) and inducer (EMMPRIN).
Prosdócimi FC; Rodini CO; Sogayar MC; Sousa SC; Xavier FC; Paiva KB
J Oral Pathol Med; 2014 Aug; 43(7):545-53. PubMed ID: 24484176
[TBL] [Abstract][Full Text] [Related]
7. Expression of matrix metalloproteinase 2 and extracellular matrix metalloproteinase inducer are unfavorable postoperative prognostic factors in intrahepatic cholangiocarcinoma.
Zhang C; Tu Z; Du S; Wang Y; Wang Q
Pathol Oncol Res; 2010 Mar; 16(1):47-53. PubMed ID: 19629755
[TBL] [Abstract][Full Text] [Related]
8. Cellular localization of EMMPRIN predicts prognosis of patients with operable lung adenocarcinoma independent from MMP-2 and MMP-9.
Sienel W; Polzer B; Elshawi K; Lindner M; Morresi-Hauf A; Vay C; Eder F; Passlick B; Klein CA
Mod Pathol; 2008 Sep; 21(9):1130-8. PubMed ID: 18567995
[TBL] [Abstract][Full Text] [Related]
9. The role of extracellular matrix metalloproteinase inducer glycosylation in regulating matrix metalloproteinases in periodontitis.
Zhang Z; Yang X; Zhang H; Liu X; Pan S; Li C
J Periodontal Res; 2018 Jun; 53(3):391-402. PubMed ID: 29315565
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of EMMPRIN and MMP-2 in the prognosis of primary cutaneous malignant melanoma.
Chen T; Zhu J
Med Oncol; 2010 Dec; 27(4):1185-91. PubMed ID: 19921476
[TBL] [Abstract][Full Text] [Related]
11. Emmprin, a cell surface inducer of matrix metalloproteinases (MMPs), is expressed in T-cell lymphomas.
Nabeshima K; Suzumiya J; Nagano M; Ohshima K; Toole BP; Tamura K; Iwasaki H; Kikuchi M
J Pathol; 2004 Mar; 202(3):341-51. PubMed ID: 14991900
[TBL] [Abstract][Full Text] [Related]
12. VEGF and EMMPRIN expression correlates with survival of patients with osteosarcoma.
Zhou Q; Zhu Y; Deng Z; Long H; Zhang S; Chen X
Surg Oncol; 2011 Mar; 20(1):13-9. PubMed ID: 19836228
[TBL] [Abstract][Full Text] [Related]
13. Clinical implications and prognostic value of EMMPRIN/CD147 and MMP2 expression in pediatric gliomas.
Gu J; Zhang C; Chen R; Pan J; Wang Y; Ming M; Gui W; Wang D
Eur J Pediatr; 2009 Jun; 168(6):705-10. PubMed ID: 18795327
[TBL] [Abstract][Full Text] [Related]
14. Elevated expression of extracellular matrix metalloproteinase inducer (CD147) and membrane-type matrix metalloproteinases in venous leg ulcers.
Norgauer J; Hildenbrand T; Idzko M; Panther E; Bandemir E; Hartmann M; Vanscheidt W; Herouy Y
Br J Dermatol; 2002 Dec; 147(6):1180-6. PubMed ID: 12452868
[TBL] [Abstract][Full Text] [Related]
15. Membrane type 1 matrix metalloproteinase (MT1-MMP/MMP-14) cleaves and releases a 22-kDa extracellular matrix metalloproteinase inducer (EMMPRIN) fragment from tumor cells.
Egawa N; Koshikawa N; Tomari T; Nabeshima K; Isobe T; Seiki M
J Biol Chem; 2006 Dec; 281(49):37576-85. PubMed ID: 17050542
[TBL] [Abstract][Full Text] [Related]
16. Extracellular matrix metalloproteinase inducer is a negative prognostic factor of pediatric medulloblastoma.
Chu T; Chen X; Yu J; Xiao J; Fu Z
Pathol Oncol Res; 2011 Sep; 17(3):705-11. PubMed ID: 21448785
[TBL] [Abstract][Full Text] [Related]
17. Expression of extracellular matrix metalloproteinase inducer (EMMPRIN) and its related extracellular matrix degrading enzymes in the endometrium during estrous cycle and early gestation in cattle.
Mishra B; Kizaki K; Koshi K; Ushizawa K; Takahashi T; Hosoe M; Sato T; Ito A; Hashizume K
Reprod Biol Endocrinol; 2010 Jun; 8():60. PubMed ID: 20540754
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase 2 in epithelial ovarian cancer.
Sillanpää S; Anttila M; Suhonen K; Hämäläinen K; Turpeenniemi-Hujanen T; Puistola U; Tammi M; Sironen R; Saarikoski S; Kosma VM
Tumour Biol; 2007; 28(5):280-9. PubMed ID: 17962725
[TBL] [Abstract][Full Text] [Related]
19. Interaction between the Wnt/β-catenin signaling pathway and the EMMPRIN/MMP-2, 9 route in periodontitis.
Liu X; Zhang Z; Pan S; Shang S; Li C
J Periodontal Res; 2018 Oct; 53(5):842-852. PubMed ID: 29900539
[TBL] [Abstract][Full Text] [Related]
20. Expression and clinical significance of extracellular matrix metalloproteinase inducer, EMMPRIN/CD147, in human osteosarcoma.
Lu Q; Lv G; Kim A; Ha JM; Kim S
Oncol Lett; 2013 Jan; 5(1):201-207. PubMed ID: 23255920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
